Clinical Trials
88 trialsNK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
SABRE
Children's National Research Institute
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
MRG003
Sun Yat-sen University
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Stanford University
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
VEGAS
Baylor College of Medicine
NYMC195
New York Medical College
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
CLOVER-2
Cellectar Biosciences, Inc.
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Baylor College of Medicine
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
Aflac-NBL-2002
Emory University
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Children's National Research Institute
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Y-mAbs Therapeutics
AflacST1501
Emory University
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Children's National Research Institute
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
University of Wisconsin, Madison
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
South Plains Oncology Consortium
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Oncurious NV
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Aflac ST0901
Emory University
AflacST1402
Emory University
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
HGS-ETR2 to Treat Children With Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
National Institutes of Health Clinical Center (CC)
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
National Institutes of Health Clinical Center (CC)
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
University of Texas Southwestern Medical Center
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Nationwide Children's Hospital
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
New York Medical College
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
A Vaccine Study for High Risk Cancers
Penn State University